Oxeladin

Summary

Oxeladin (CHEMBL1500276) is an approved small molecule (ATC R05DB09); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R05DB09
• Indications: 1 condition
• Chemistry: 335.5 Da · C20H33NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1500276
Name	Oxeladin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4619
ATC	R05DB09
Molecular formula	C20H33NO3
Molecular weight	335.5
InChIKey	IQADUMSPOQKAAO-UHFFFAOYSA-N

SMILES: CCC(CC)(C1=CC=CC=C1)C(=O)OCCOCCN(CC)CC

IUPAC name: 2-[2-(diethylamino)ethoxy]ethyl 2-ethyl-2-phenylbutanoate

Also known as: Oxeladin, Oxeladina, Oxeladine, SID26660767, OXELADIN, OXELAIDIN CITRATE

Parent form; salt/anhydrous children: CHEMBL2354637

Patent coverage: 238 distinct patent families (842 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).